Dr. O'Connor on Real-World Results With Regorafenib in mCRC

Juan Manuel O’Connor, MD, head, Department Gastrointestinal Oncology, Department of Clinical Oncology, Institute Alexander Fleming, Buenos Aires, discusses real-world results with regorafenib (Stivarga) in the treatment of patients with metastatic colorectal cancer (mCRC).

In a presentation of the final results from the prospective, observational CORRELATE study at the 2018 ESMO Congress, real-world dosing data were revealed for regorafenib in patients with mCRC. Of the 1037 patients eligible for evaluation, results indicated that 57% started treatment at 160 mg, 30% of patients began at 120 mg, and 13% began at ≤80 mg.

The take-home message of the study, says O’Connor, is that despite the differences in starting dose, there was no impact on the median overall survival and median progression-free survival. Moving forward, it is important to consider data from the real-world setting, states O’Connor, as there may be differences in the data demonstrated in clinical trials versus the clinic.